Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Invested Capital (2016 - 2025)

Enanta Pharmaceuticals' Return on Invested Capital history spans 12 years, with the latest figure at 0.75% for Q4 2025.

  • For Q4 2025, Return on Invested Capital rose 17.0% year-over-year to 0.75%; the TTM value through Dec 2025 reached 0.75%, up 17.0%, while the annual FY2025 figure was 0.86%, 16.0% down from the prior year.
  • Return on Invested Capital reached 0.75% in Q4 2025 per ENTA's latest filing, up from 1.16% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.21% in Q1 2021 to a low of 1.16% in Q3 2025.
  • Average Return on Invested Capital over 5 years is 0.63%, with a median of 0.58% recorded in 2023.
  • The largest YoY upside for Return on Invested Capital was 17bps in 2025 against a maximum downside of -36bps in 2025.
  • A 5-year view of Return on Invested Capital shows it stood at 0.45% in 2021, then rose by 11bps to 0.4% in 2022, then crashed by -79bps to 0.71% in 2023, then tumbled by -30bps to 0.92% in 2024, then grew by 18bps to 0.75% in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Return on Invested Capital are 0.75% (Q4 2025), 1.16% (Q3 2025), and 1.12% (Q2 2025).